1. AB0417 EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS ACCORDING TO DURATION OF PRIOR CSDMARD TREATMENT AND NUMBER OF PRIOR CSDMARDS: A POST HOC ANALYSIS OF PHASE 3 AND PHASE 3B/4 TRIALS. (June 2019) Authors: Aletaha, Daniel; Gomez-Reino, Juan Jose; Burmester, Gerd Rdiger; Vollenhoven, Ronald van; Luis Rivas, Jose; Benkhalifa, Salim; Dahl, Palle; Shi, Harry; Wang, Lisy Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 1671 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LB0004 METHOTREXATE WITHDRAWAL IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVE LOW DISEASE ACTIVITY WITH TOFACITINIB MODIFIED-RELEASE 11 MG ONCE DAILY + METHOTREXATE: A RANDOMISED NON-INFERIORITY PHASE 3B/4 STUDY. (June 2019) Authors: B. Cohen, Stanley; Pope, Janet; Haraoui, Boulos; Irazoque-Palazuelos, Fedra; Korkosz, Mariusz; Diehl, Annette; Luis Rivas, Jose; Lukic, Tatjana; Liu, Shixue; Stockert, Lori; Iikuni, Noriko; Keystone, Edward Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 260 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗